Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Overview of attention for article published in The Lancet Respiratory Medicine, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
twitter: 32 X users

wikipedia: 2 Wikipedia pages
reddit: 1 Redditor

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 36 X posts from 32 X users, with an upper bound of 251,602 followers.

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19 : a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial https://t.co/b9Wt062sZp #OpenAccess

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19 : a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial https://t.co/o1BiawAtNl

RT @NeumoMadrid: Dipeptidyl peptidase-1 inhibition in patients hospitalised with #Covid19 https://t.co/ZhBx6uNgZX by @TheLancet https://t.c…

Dipeptidyl peptidase-1 inhibition in patients hospitalised with #Covid19 https://t.co/ZhBx6uNgZX by @TheLancet https://t.co/K2i1CCkMRH

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 32 additional X posts.